In the attached article, from The Economist, investors are hoping that medical psychedelics will be the new cannabis.
It briefly looks at how Ketamine and psilocybin (which gives mushrooms their magic) are being researched for their potential effects on psychiatric conditions such as depression, anxiety, and addiction.
The Economist. (2019) Medical Psychedelics: Shroom to Grow. The Economist. 16 October 2019.